$OPCH
Option Care Health, Inc. Stock $opch

$opch Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000101473915000012 Filed on August 10, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q4
Revenue	$247.2M	$246.9M	$239.7M
YoY Change	1.34%	-0.09%	6.32%
Cost Of Revenue	$182.0M	$182.1M	$170.9M
YoY Change	6.62%	0.17%	8.65%
Gross Profit	$65.23M	$64.82M	$63.68M
YoY Change	4.06%	4.13%	-6.63%
Gross Profit Margin	26.39%	26.25%	26.56%
Selling, General & Admin	$17.90M	$27.00M	$87.70M
YoY Change	-78.22%	-54.85%	26.55%
% of Gross Profit	27.44%	41.66%	137.72%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.029M	$4.130M	$1.700M
YoY Change	-4.19%	4.35%	-10.53%
% of Gross Profit	6.18%	6.37%	2.67%
Operating Expenses	$65.60M	$76.50M	$105.2M
YoY Change	-21.62%	34.92%	59.88%
Operating Profit	-$19.28M	-$254.0M	-$41.52M
YoY Change	-30.4%	3860.78%	-1832.97%
Interest Expense	-$9.500M	-$9.100M	-$9.300M
YoY Change	-199.34%	-199.62%	16.25%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$28.79M	-$264.8M	-$60.63M
YoY Change	-22.76%	1437.79%	365.96%
Income Tax	-$4.551M	-$19.92M	$2.700M
% Of Pretax Income
Net Earnings	-$16.78M	-$244.8M	-$63.63M
YoY Change	-56.64%	1135.28%	242.83%
Net Earnings / Revenue	-6.79%	-99.15%	-26.54%
Basic Earnings Per Share
Diluted Earnings Per Share	-$976.7K	-$14.23M	-$3.698M
COMMON SHARES
Basic Shares Outstanding	68.73M shares	68.65M shares	68.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.40M	$1.200M	$700.0K
YoY Change		-20.0%	-30.0%
Cash & Equivalents	$29.44M	$1.173M	$740.0K
Short-Term Investments
Other Short-Term Assets	$21.90M	$10.40M	$18.70M
YoY Change	97.3%	-15.45%	-36.39%
Inventory	$26.89M	$42.36M	$37.22M
Prepaid Expenses
Receivables	$121.2M	$131.5M	$140.8M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$199.4M	$185.4M	$188.2M
YoY Change	-7.49%	-22.36%	-20.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.11M	$34.91M	$38.17M
YoY Change	-14.84%	-12.43%	-7.31%
Goodwill	$308.7M	$335.3M	$573.3M
YoY Change	-46.15%	-41.47%	0.35%
Intangibles			$10.27M
YoY Change			-38.96%
Long-Term Investments
YoY Change
Other Assets	$1.158M	$1.192M	$1.272M
YoY Change	-9.18%	-9.56%	-65.93%
Total Long-Term Assets	$363.2M	$391.7M	$636.5M
YoY Change	-43.53%	-39.27%	-9.06%
TOTAL ASSETS
Total Short-Term Assets	$199.4M	$185.4M	$188.2M
Total Long-Term Assets	$363.2M	$391.7M	$636.5M
Total Assets	$562.7M	$577.1M	$824.7M
YoY Change	-34.49%	-34.7%	-11.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$53.38M	$77.09M	$89.20M
YoY Change	-28.68%	10.52%	40.31%
Accrued Expenses	$50.40M	$47.60M	$53.80M
YoY Change	26.32%	4.16%	39.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$39.60M	$200.0K	$5.395M
YoY Change	708.16%	-50.0%	-91.05%
Total Short-Term Liabilities	$146.8M	$134.0M	$163.3M
YoY Change	8.35%	6.72%	-7.41%
LONG-TERM LIABILITIES
Long-Term Debt	$409.3M	$418.6M	$418.4M
YoY Change	-2.17%	0.07%	11.48%
Other Long-Term Liabilities	$6.793M	$6.891M	$8.129M
YoY Change	-17.71%	-19.68%	-53.65%
Total Long-Term Liabilities	$6.793M	$6.891M	$8.129M
YoY Change	-17.71%	-19.68%	-97.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$146.8M	$134.0M	$163.3M
Total Long-Term Liabilities	$6.793M	$6.891M	$8.129M
Total Liabilities	$563.0M	$562.5M	$607.9M
YoY Change	-2.98%	-1.12%	4.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$583.5M	-$566.7M	-$302.2M
YoY Change	144.56%	183.53%	95.3%
Common Stock	$533.1M	$534.1M	$529.7M
YoY Change	1.07%	1.7%	1.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$10.74M	$10.72M	$10.68M
YoY Change	4.13%	3.92%	3.57%
Treasury Stock Shares	2.654M shares	2.645M shares	2.637M shares
Shareholders Equity	-$61.14M	-$43.29M	$216.6M
YoY Change
Total Liabilities & Shareholders Equity	$562.7M	$577.1M	$824.7M
YoY Change	-34.49%	-34.7%	-11.97%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q4
OPERATING ACTIVITIES
Net Income	-$16.78M	-$244.8M	-$63.63M
YoY Change	-56.64%	1135.28%	242.83%
Depreciation, Depletion And Amortization	$4.029M	$4.130M	$1.700M
YoY Change	-4.19%	4.35%	-10.53%
Cash From Operating Activities	-$20.40M	-$18.20M	$300.0K
YoY Change	2814.29%	264.0%	-101.84%
INVESTING ACTIVITIES
Capital Expenditures	-$4.300M	-$3.700M	-$2.500M
YoY Change	-2.27%	-2.63%	-55.36%
Acquisitions
YoY Change
Other Investing Activities	$22.40M	$0.00	$900.0K
YoY Change		-100.0%	-57.14%
Cash From Investing Activities	$18.00M	-$3.700M	-$1.600M
YoY Change	-509.09%	12.12%	-55.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.70M	-200.0K	2.100M
YoY Change	752.78%	-140.0%	-89.9%
NET CHANGE
Cash From Operating Activities	-20.40M	-18.20M	300.0K
Cash From Investing Activities	18.00M	-3.700M	-1.600M
Cash From Financing Activities	30.70M	-200.0K	2.100M
Net Change In Cash	28.30M	-22.10M	800.0K
YoY Change	-1986.67%	183.33%	-11.11%
FREE CASH FLOW
Cash From Operating Activities	-$20.40M	-$18.20M	$300.0K
Capital Expenditures	-$4.300M	-$3.700M	-$2.500M
Free Cash Flow	-$16.10M	-$14.50M	$2.800M
YoY Change	-535.14%	1108.33%	-126.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	bios	Adjusted Ebitda AdjustedEbitda	3786000	USD
	bios	Adjustmentsto Additional Paidin Capital Accretionof Discounton Temporary Equity AdjustmentstoAdditionalPaidinCapitalAccretionofDiscountonTemporaryEquity	3350000	USD
	bios	Adjustmentsto Additional Paidin Capital Increasein Liquidation Preferenceon Temporary Equity AdjustmentstoAdditionalPaidinCapitalIncreaseinLiquidationPreferenceonTemporaryEquity	2258000	USD
CY2014Q4	bios	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	46092000	USD
CY2015Q2	bios	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	40923000	USD
CY2014Q2	bios	Acquisition And Integration Expenses AcquisitionAndIntegrationExpenses	5333000	USD
	bios	Acquisition And Integration Expenses AcquisitionAndIntegrationExpenses	11832000	USD
CY2015Q2	bios	Acquisition And Integration Expenses AcquisitionAndIntegrationExpenses	259000	USD
	bios	Acquisition And Integration Expenses AcquisitionAndIntegrationExpenses	479000	USD
CY2014Q2	bios	Adjusted Ebitda AdjustedEbitda	11015000	USD
	bios	Adjusted Ebitda AdjustedEbitda	20175000	USD
CY2015Q2	bios	Adjusted Ebitda AdjustedEbitda	-2534000	USD
	bios	Adjustmentsto Additional Paidin Capital Private Investmentin Public Equity Transaction AdjustmentstoAdditionalPaidinCapitalPrivateInvestmentinPublicEquityTransaction	6570000	USD
CY2014Q4	bios	Allowancefor Doubtful Accounts Percentageof Accounts Receivable AllowanceforDoubtfulAccountsPercentageofAccountsReceivable	0.321
CY2015Q2	bios	Allowancefor Doubtful Accounts Percentageof Accounts Receivable AllowanceforDoubtfulAccountsPercentageofAccountsReceivable	0.355
CY2014Q4	bios	Amounts Due To Plan Sponsors AmountsDueToPlanSponsors	5779000	USD
CY2015Q2	bios	Amounts Due To Plan Sponsors AmountsDueToPlanSponsors	4254000	USD
	bios	Classof Warrantor Right Exercise Priceof Warrantsor Rights Percentageof Market Price ClassofWarrantorRightExercisePriceofWarrantsorRightsPercentageofMarketPrice	0.85
CY2015Q2	bios	Finite Lived Intangible Assets Amortization Expense Year Fiveand Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandThereafter	0	USD
CY2014Q2	bios	Gain Losson Changein Fair Valueof Contingent Consideration GainLossonChangeinFairValueofContingentConsideration	4646000	USD
	bios	Gain Losson Changein Fair Valueof Contingent Consideration GainLossonChangeinFairValueofContingentConsideration	6855000	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	5644000	USD
CY2015Q2	bios	Gain Losson Changein Fair Valueof Contingent Consideration GainLossonChangeinFairValueofContingentConsideration	93000	USD
	bios	Gain Losson Changein Fair Valueof Contingent Consideration GainLossonChangeinFairValueofContingentConsideration	72000	USD
	bios	Increase Decreasein Amounts Due To Plan Sponsor IncreaseDecreaseinAmountsDueToPlanSponsor	816000	USD
	bios	Increase Decreasein Amounts Due To Plan Sponsor IncreaseDecreaseinAmountsDueToPlanSponsor	-1524000	USD
	bios	Increase Decreasein Fair Valueof Contingent Consideration IncreaseDecreaseinFairValueofContingentConsideration	6855000	USD
	bios	Increase Decreasein Fair Valueof Contingent Consideration IncreaseDecreaseinFairValueofContingentConsideration	72000	USD
	bios	Increasein Accounts Receivable Outstandingover One Hundred Eight Days IncreaseinAccountsReceivableOutstandingoverOneHundredEightDays	700000	USD
CY2014Q4	bios	Long Term Debt And Capital Lease Obligations Total LongTermDebtAndCapitalLeaseObligationsTotal	423803000	USD
CY2015Q2	bios	Long Term Debt And Capital Lease Obligations Total LongTermDebtAndCapitalLeaseObligationsTotal	418857000	USD
CY2014	bios	Number Of Large Markets NumberOfLargeMarkets	7	Market
CY2014	bios	Number Of Legacy Billing Systems NumberOfLegacyBillingSystems	5	System
	bios	Number Of Types Of Accounts Receivable NumberOfTypesOfAccountsReceivable	3	accounts_receivable
CY2014Q2	bios	Other Interest Income Expense Net OtherInterestIncomeExpenseNet	11000	USD
	bios	Other Interest Income Expense Net OtherInterestIncomeExpenseNet	42000	USD
CY2015Q2	bios	Other Interest Income Expense Net OtherInterestIncomeExpenseNet	76000	USD
	bios	Other Interest Income Expense Net OtherInterestIncomeExpenseNet	249000	USD
	bios	Proceedsfrom Issuanceof Convertible Preferred Stockand Warrants ProceedsfromIssuanceofConvertiblePreferredStockandWarrants	0	USD
	bios	Proceedsfrom Issuanceof Convertible Preferred Stockand Warrants ProceedsfromIssuanceofConvertiblePreferredStockandWarrants	58951000	USD
CY2015Q1	bios	Proceedsfrom Issuanceof Equityand Temporary Equity ProceedsfromIssuanceofEquityandTemporaryEquity	62500000	USD
CY2015Q1	bios	Proceedsfrom Issuanceof Temporary Equity ProceedsfromIssuanceofTemporaryEquity	59355000	USD
	bios	Registration Rights Agreement Periodof Timebefore Rights Become Effective RegistrationRightsAgreementPeriodofTimebeforeRightsBecomeEffective	P1Y
	bios	Repayments Of Debt Including Accrued Interest RepaymentsOfDebtIncludingAccruedInterest	45300000	USD
CY2014Q2	bios	Restructuring Charges Other Expensesand Investments RestructuringChargesOtherExpensesandInvestments	4519000	USD
	bios	Restructuring Charges Other Expensesand Investments RestructuringChargesOtherExpensesandInvestments	10021000	USD
CY2015Q2	bios	Restructuring Charges Other Expensesand Investments RestructuringChargesOtherExpensesandInvestments	5803000	USD
	bios	Restructuring Charges Other Expensesand Investments RestructuringChargesOtherExpensesandInvestments	9266000	USD
CY2015Q1	bios	Stock Purchase Agreement Covenant Terms Minimum Percentageof Proceedstobe Usedon Repaymentof Debt StockPurchaseAgreementCovenantTermsMinimumPercentageofProceedstobeUsedonRepaymentofDebt	0.75
	bios	Stock Purchase Agreement Percentageof Proceeds Usedto Repayof Debt StockPurchaseAgreementPercentageofProceedsUsedtoRepayofDebt	0.77
CY2014Q2	bios	Transitional Expenses TransitionalExpenses	900000	USD
	bios	Transitional Expenses TransitionalExpenses	1600000	USD
CY2015Q2	bios	Transitional Expenses TransitionalExpenses	4200000	USD
	bios	Transitional Expenses TransitionalExpenses	6700000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001014739
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68730871	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	BioScrip, Inc.
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	90032000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	77085000	USD
CY2014Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	207310000	USD
CY2015Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	203803000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	140810000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	131471000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	50643000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	56947000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	529682000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	534100000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	34000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4665000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3454000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	66500000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	72332000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	66500000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	72332000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	5800000	USD
CY2014Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	129000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	195000	USD
CY2015Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	142000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	282000	USD
CY2014Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	727000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2550000	USD
CY2015Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	693000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1334000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2745000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1792000	USD
CY2014Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1620000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3323000	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1489000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2979000	USD
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3900000	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5600000	shares
CY2014Q4	us-gaap	Assets Assets	824713000	USD
CY2015Q2	us-gaap	Assets Assets	577149000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	188215000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	185403000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	376000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	11000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	62000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	122000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	181000	USD
CY2014Q2	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	700000	USD
	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	1100000	USD
CY2015Q2	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	600000	USD
	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	1300000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1001000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1547000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	740000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1172000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	546000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	432000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	57688000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-4304000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-4110000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71274064	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71376164	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68636965	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68730871	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2015Q2	us-gaap	Contractual Obligation ContractualObligation	29431000	USD
CY2015Q2	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	2357000	USD
CY2015Q2	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	2731000	USD
CY2015Q2	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	4724000	USD
CY2015Q2	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	8043000	USD
CY2015Q2	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	6835000	USD
CY2015Q2	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	4741000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	181769000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	355962000	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	196397000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	391605000	USD
CY2014Q2	us-gaap	Cost Of Services CostOfServices	20111000	USD
	us-gaap	Cost Of Services CostOfServices	42564000	USD
CY2015Q2	us-gaap	Cost Of Services CostOfServices	19634000	USD
	us-gaap	Cost Of Services CostOfServices	40895000	USD
CY2014Q2	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015Q2	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-587000	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	196000	USD
CY2015Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29000	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30000	USD
CY2014Q2	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-587000	USD
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	196000	USD
CY2015Q2	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	29000	USD
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	30000	USD
CY2014Q2	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3248000	USD
	us-gaap	Depreciation Depreciation	7794000	USD
CY2015Q2	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-16816000	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-15188000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	13463000	USD
CY2015Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	13035000	USD
CY2014Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3650000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	6358000	USD
CY2015Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-19950000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-18023000	USD
CY2014Q2	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	402000	USD
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	714000	USD
CY2015Q2	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3134000	USD
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2835000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	19058000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	2924000	USD
CY2014Q2	us-gaap	Depreciation Depreciation	3958000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	4130000	USD
	us-gaap	Depreciation Depreciation	8434000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.62
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.93
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23081000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	26060000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2162000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	67000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1983000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3078000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	33350000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	33350000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10269000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7290000	USD
CY2014Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2014Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		USD
CY2015Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-628000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-628000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-628000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	573323000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	335323000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2014Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	238000000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	238000000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	65356000	USD
	us-gaap	Gross Profit GrossProfit	130456000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17993000	USD
CY2014Q2	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8755000	USD
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	43977000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	65966000	USD
	us-gaap	Gross Profit GrossProfit	132439000	USD
CY2014Q2	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	161658000	USD
	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	313398000	USD
CY2015Q2	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	176763000	USD
	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	350710000	USD
CY2014Q2	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	225277000	USD
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	441180000	USD
CY2015Q2	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	241020000	USD
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	480067000	USD
CY2014Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	21848000	USD
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	45238000	USD
CY2015Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	21343000	USD
CY2014Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	247125000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	486418000	USD
CY2015Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	262363000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	524044000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-18611000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-43867000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-243164000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-259069000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15548000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37313000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-263085000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-277062000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.27
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.64
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-3.60
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-3.85
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1207000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1265000	USD
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1644000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-5412000	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.02
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.08
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3063000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6554000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19921000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19356000	USD
CY2015Q2	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	31098000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	37879000	USD
CY2014Q2	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5374000	USD
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13044000	USD
CY2015Q2	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-92080000	USD
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-96972000	USD
CY2014Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	66000	USD
	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	117000	USD
CY2015Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	71000	USD
	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	110000	USD
CY2014Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	USD
	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	USD
CY2015Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	40977000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	58000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5149000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1116000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-8335000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3745000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	613000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	19019000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-10299000	USD
CY2014Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9135000	USD
	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	40977000	USD
CY2014Q2	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-384000	USD
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	125000	USD
CY2015Q2	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	11000	USD
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	11000	USD
CY2014Q2	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	0	USD
	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	0	USD
CY2015Q2	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2000	USD
	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	349000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	515000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	6105000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-12912000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-6358000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	15834000	USD
	us-gaap	Increase Decrease In Future Policy Benefit Reserves IncreaseDecreaseInFuturePolicyBenefitReserves	1475000	USD
	us-gaap	Increase Decrease In Future Policy Benefit Reserves IncreaseDecreaseInFuturePolicyBenefitReserves	-3346000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	4764000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-148000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-19634000	USD
CY2015Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9080000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-18243000	USD
	us-gaap	Interest Paid Net InterestPaidNet	12232000	USD
	us-gaap	Interest Paid Net InterestPaidNet	18391000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	6853000	USD
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	6705000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	37215000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	42364000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1218000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-270089000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	824713000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	577149000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6413000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17679000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-254005000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-258819000	USD
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2000000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3900000	USD
CY2015Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1800000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3700000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	607908000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	562455000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	162313000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	134021000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	418408000	USD
CY2015Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	418619000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5395000	USD
CY2015Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	238000	USD
CY2014Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	15000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18785000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52390000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	50309000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5797000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-7379000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5797000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30978000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46161000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26674000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-42051000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-19818000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45132000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-244808000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-264481000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19818000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45132000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-248799000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	29055000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2731000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4713000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6773000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7921000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2357000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	4560000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1272000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1192000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8129000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6891000	USD
CY2014Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	57244000	USD
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	116424000	USD
CY2015Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	60367000	USD
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	118140000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	6925000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	5797000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1161000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	454000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4175000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9450000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10396000	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	193868000	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3145000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	85400000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	129163000	USD
	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-172243000	USD
	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	905000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	88814000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	91853000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38171000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34906000	USD
CY2014Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8360000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14961000	USD
CY2015Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	15146000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	23466000	USD
CY2015Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	23300000	USD
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	140810000	USD
CY2015Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	131471000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	151000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	345000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	125403000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	134163000	USD
CY2014Q2	us-gaap	Restructuring Charges RestructuringCharges	3858000	USD
	us-gaap	Restructuring Charges RestructuringCharges	8450000	USD
CY2015Q2	us-gaap	Restructuring Charges RestructuringCharges	4803000	USD
	us-gaap	Restructuring Charges RestructuringCharges	8266000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-302206000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566687000	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1998000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4884000	USD
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1162000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2819000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1858427	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	906000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	354583000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	315022000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	216805000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	-43294000	USD
CY2014Q4	us-gaap	Supplementary Insurance Information Liability For Future Policy Benefits Losses Claims And Loss Expense Reserves SupplementaryInsuranceInformationLiabilityForFuturePolicyBenefitsLossesClaimsAndLossExpenseReserves	8162000	USD
CY2015Q2	us-gaap	Supplementary Insurance Information Liability For Future Policy Benefits Losses Claims And Loss Expense Reserves SupplementaryInsuranceInformationLiabilityForFuturePolicyBenefitsLossesClaimsAndLossExpenseReserves	4816000	USD
CY2014Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2015Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2186000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	3350000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2015Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	57988000	USD
CY2014Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2015Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1805000	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	2258000	USD
CY2015Q2	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	64758000	USD
CY2015Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2015Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	825000	shares
CY2015Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	625000	shares
CY2014Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2015Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	625000	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2637099	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	2645293	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	10679000	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	10715000	USD
CY2015Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2900000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68468000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68354000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68698000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68668000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change in Estimate of the Collectability of Accounts Receivable</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2014, the Company experienced deterioration in the aging of certain accounts receivable primarily due to delays and disruptions related to the integration of its acquisitions in 2013. The disruption to billing and collection processes was attributable in part to the following:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Re-licensure and new managed care credentialing was required in connection with the CarePoint Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare claims were not filed until retraining and review of eligibility was performed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merged facilities and work teams in </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> large markets and related employee turnover;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion to a single version of our dispensing and billing system while still managing accounts receivable run-off on </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> other legacy versions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash posting challenges that delayed secondary and patient billings and patient statement issuance.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company outsourced collections to third party agency partners and hired and trained billing and collection personnel to mitigate the effects of the disruption, however, the Company experienced more difficulty collecting the aged balances than it originally estimated. The Company provided incremental allowances in each quarter during 2014 to address the developing deterioration, and as such the Company materially changed its estimates based on actual collection experience during and after the acquisition disruption period. </font></div></div>

Files In Submission

Name	View Source	Status
0001014739-15-000012-index-headers.html	Edgar Link	pending
0001014739-15-000012-index.html	Edgar Link	pending
0001014739-15-000012.txt	Edgar Link	pending
0001014739-15-000012-xbrl.zip	Edgar Link	pending
bios-20150630.xml	Edgar Link	completed
bios-20150630.xsd	Edgar Link	pending
bios-20150630x10q.htm	Edgar Link	pending
bios-20150630_cal.xml	Edgar Link	unprocessable
bios-20150630_def.xml	Edgar Link	unprocessable
bios-20150630_lab.xml	Edgar Link	unprocessable
bios-20150630_pre.xml	Edgar Link	unprocessable
bios-ex311x2015063010xq.htm	Edgar Link	pending
bios-ex312x2015063010xq.htm	Edgar Link	pending
bios-ex321x2015063010xq.htm	Edgar Link	pending
bios-ex322x2015063010xq.htm	Edgar Link	pending
esppamendmenteffectiveapri.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
formofmarket-basedcashawar.htm	Edgar Link	pending
logowithregisteredtm01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPCH
Option Care Health, Inc. Stock $opch

2015 Q3 Form 10-Q Financial Statement

#000101473915000012 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPCH Option Care Health, Inc. Stock $opch

2015 Q3 Form 10-Q Financial Statement

#000101473915000012 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPCH
Option Care Health, Inc. Stock $opch